STAT3 and Hepatic fibrosis: Umbilical-cord-derived MSCs and also allogenic ABCB5-positive MSCs that improve liver fibrosis enhance regeneration, suppress inflammation, and downregulate Notch and Stat1/Stat3 signaling in rats (163) are under clinical trials (NCT04822922, NCT03860155) for the treatment of patients with ACLF.